Sentaur Biosciences started its operations in 2018. The company develops antibodies to specifically target senescent cells. The technology comes from the Weizmann Institute, from the lab of Prof. Valery Krizhanovsky, a world renown expert in the field of Senescence Cells. The team developed a unique MS based discovery method to identify novel targets onto the surface of senescence cells. Sentaur Biosciences focuses on those identified targets and develops antibodies to target and eliminate the senescent cells. The company operates out of M Ventures Bioincubator in Yavne, Israel.